Cardiorenal InteractionsInsights From the ESCAPE Trial
Anju Nohria, MD*,
Vic Hasselblad, PhD ,
Amanda Stebbins, PhD,
Daniel F. Pauly, MD, PhD ,
Gregg C. Fonarow, MD ,
Monica Shah, MD,
Clyde W. Yancy, MD¶,
Robert M. Califf, MD,
Lynne W. Stevenson, MD* and
James A. Hill, MD,*
* Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
Duke University Medical Center, Durham, North Carolina
University of Florida College of Medicine, Gainesville, Florida
Ahmanson-UCLA Cardiomyopathy Center, UCLA Division of Cardiology, Los Angeles, California
¶ UT Southwestern Medical School, Dallas, Texas.
View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Impact of PAC on Worsening Renal Function in Patients Stratified by Baseline Renal Function
Patients were stratified based on their admission estimated glomerular filtration rate (eGFR) into those with (eGFR <60 ml/min) and without (eGFR  60 ml/min) baseline renal insufficiency. A pulmonary artery catheter-guided treatment strategy (PAC) did not reduce the incidence of worsening renal function (defined as a 0.3 mg/dl increase in serum creatinine from baseline to discharge) in either eGFR group relative to a strategy based on clinical assessment alone (CLIN).
|
|
|
